Inhibitex Reports of the interim results of phase II clinical trial of FV-100

Inhibitex, Inc. announced that the independent Data Safety Monitoring Board responsible for reviewing the company’s safety data is ongoing Phase II clinical trials of FV-100 has met, as expected, after the company had provided 30-day follow-up data on the first half of the patients that the company plans to enter into the process. Based on the results of these reviews, the process will continue as originally designed, without any modification. The company, which is blind efficacy data, provides high-end test data will be available by the fourth quarter of 2010.The cap can stomach much less invasive tests. This means a huge boost in acceptability for the patient, said Dr.

Jean-Francois Rey Arnault Tzanck Institute to.